Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: A randomized controlled trial in Ghana

Bulletin of the World Health Organization

Volumn 76, Issue 4, 1998, Pages 353-359

  Nkrumah, F K ^a   Osei Kwasi, M ^b   Dunyo, S K ^c   Koram, K A ^c   Afari, E A ^c  

^a University of Ghana   (Ghana)

^b Virology Unit

^c Epidemiology Unit

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

CHILD HEALTH; HEALTH CARE; MEASLES; VACCINATION;

ACTIVE IMMUNIZATION; ARTICLE; DOSE RESPONSE; ENDEMIC DISEASE; GHANA; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; MEASLES; MEASLES VACCINATION;

AFRICA; AFRICA SOUTH OF THE SAHARA; AGE FACTORS; CHILD HEALTH SERVICES; COMPARATIVE STUDIES; DELIVERY OF HEALTH CARE; DEMOGRAPHIC FACTORS; DEVELOPING COUNTRIES; DISEASES; ENGLISH SPEAKING AFRICA; GHANA; HEALTH; HEALTH SERVICES; IMMUNIZATION; INFANT; MATERNAL-CHILD HEALTH SERVICES; MEASLES--PREVENTION AND CONTROL; POPULATION; POPULATION CHARACTERISTICS; PRIMARY HEALTH CARE; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; VACCINATION; VACCINES--ADMINISTRACTION AND DOSAGE; VIRAL DISEASES; WESTERN AFRICA; YOUTH;

AGE FACTORS; ANTIBODIES, VIRAL; DATA INTERPRETATION, STATISTICAL; ENDEMIC DISEASES; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; GHANA; HUMANS; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; TIME FACTORS;

GHANA;

EID: 0031751112     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hull HP, Williams PJ, Oldfield F. Measles mortali and vaccine efficacy in rural West Africa. Lancet 1983, 1: 972-975.
2. Loening VE, Coovadia HM. Age-specific occurrence rates of measles in urban, periurban, and rural environments: implications for time of vaccination. Lancet, 1983, 2: 324-326.
3. Osagie HF. Delayed mortality and morbidity months after measles in young children in Nigeria MSc. thesis, Institute of Child Health, University London, 1986.
4. Albrecht P et al. Persistence of maternal antibody infants beyond 12 months: mechanism of measles vaccine failure. Journal of pediatrics, 1977, 91: 715-718.
5. Ministries of Health of Brazil, Chile, Costa Rica and Ecuador, and the Pan American Health Organization. Seroconversion rates and measles antibody titer induced by measles vaccine in Latin American children 6-12 months of age. Bulletin of the P American Health Organization, 1982, 16: 272-285.
6. Black FL et al. Inadequate immunity to measles children vaccinated at an early age: effect of revaccination. Bulletin of the World Health Organization, 1984, 62: 315-319.
7. Dabis F et al. The epidemiology of measles in a partially vaccinated population in an African city: implications for immunization programs. American journal of epidemiology, 1988, 127: 171-178.
8. Taylor WR et al. Measles control in urban Africa complicated by high incidence of measles in the first year of life. American journal of epidemiology, 1988, 127: 788-794.
9. Khanum S et al. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccines given by aerosol or subcutaneous injection. Lancet, 1987, 1: 150-153.
10. Sabin AB et al. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. 1. Different results with undiluted human diploid-cell and chick-embryo fibroblast vaccines. Journal of the American Medical Association, 1983, 249: 2651-2662.
11. Ueda S et al. Studies on further attenuated measles live vaccine. II. Correlation between the titre of the vaccine, the antibody response, and clinical reactions. Biken journal, 1970, 13: 117-120.
12. Bolotovski VM et al. Immunization of 6- and 9-month-old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. International journal of epidemiology, 1994, 23: 1069-1077.
13. Whittle H et al. Trial of Edmonsten-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet, 1988, 2: 811-816.
14. Whittle HC et al. Immunisation of 4-6-month-old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet, 1984, 2: 834-837.
15. WHO Expanded Programme on Immunization. Global Advisory Group. Weekly epidemiological record, 1990, 65(2): 5-11; 1990, 65(3): 15-16.
16. WHO Expanded Programme on Immunization. Global Advisory Group. Weekly epidemiological record, 1990, 65(2): 5-11; 1990, 65(3): 15-16.
17. Garene M et al. Child mortality after high-titre measles vaccine: prospective study in Senegal. Lancet, 1991, 2: 903-907
18. WHO Expanded Programme on Immunization. Global Advisory Group. Weekly epidemiological record, 1993, 68(12): 1-6; 1993, 68(3): 11-16.
19. WHO Expanded Programme on Immunization. Global Advisory Group. Weekly epidemiological record, 1993, 68(12): 1-6; 1993, 68(3): 11-16.
20. Makino S. Development and characteristics of live AIK-C measles vaccine: a brief report. Review of infectious diseases, 1983, 5: 504-505.
21. Tidjani O et al. Serological effects of EdmonstonZagreb, Schwarz and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet, 1989, 2: 1357-1360.
22. Laboratory methods for the titration of live virus vaccines using cell-culture techniques. Unpublished document WHO/BLG/EPI/89.1: 47-51 (available upon request from Biologicals, World Health Organization, 1211 Geneva 27, Switzerland).
23. Burstrom B, Aaby P, Mutie DM. Measles in infants: a review of studies on incidence, vaccine efficacy and mortality in east Africa. East African medical journal, 1995, 72: 155-161.
24. Aaby P et al. Further community studies on role of overcrowding and intensive exposure on measles mortality. Review of infectious diseases, 1988, 10: 474-477.
25. Kambarani RA et al. Measles epidemic in spite of high measles immunization coverage rates in Harare, Zimbabwe. Bulletin of the World Health Organization, 1991, 69: 213-219.
26. Malfait P et al. Measles epidemic in the urban community of Niamey: transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991. Paediatric and infectious diseases journal, 1994, 13: 38-45.